Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...

Novo Nordisk Chief Financial Officer Karsten Munk Knudsen said in an interview it takes years for a pharmaceutical company to build a factory in compliance with the quality protocols set and ...

Novo Nordisk Chief Financial Officer Karsten Munk Knudsen said in an interview it takes years for a pharmaceutical company to build a factory in compliance with the quality protocols set and enforced ...

The Novo Nordisk Foundation is not a charitable organisation ... They fund and work with organisations inside and outside Denmark, including the Centre for Childhood Health, the Center for ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug ...

Novo Nordisk NOVO.B6.64%increase; green up pointing triangle lowered its full-year guidance as copycat versions of its blockbuster weight-loss and diabetes drugs in the U.S. hold back sales of its ...

Rare disease sales increased by 5% measured in Danish kroner (3% at CER). Within R&D, Novo Nordisk completed the REDEFINE 2 trial, where CagriSema demonstrated superior weight loss of 15.7% in ...